Yousif Capital Management LLC Sells 18,897 Shares of Kenvue Inc. $KVUE

Yousif Capital Management LLC reduced its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 3.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 541,208 shares of the company's stock after selling 18,897 shares during the quarter. Yousif Capital Management LLC's holdings in Kenvue were worth $11,327,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Kenvue by 4.9% in the 1st quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company's stock worth $5,494,882,000 after buying an additional 10,600,682 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Kenvue by 2.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 25,606,238 shares of the company's stock worth $613,882,000 after buying an additional 633,461 shares in the last quarter. Boston Partners increased its stake in Kenvue by 7.4% in the 1st quarter. Boston Partners now owns 25,346,453 shares of the company's stock worth $606,920,000 after buying an additional 1,750,490 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Kenvue by 11.6% in the 1st quarter. JPMorgan Chase & Co. now owns 24,912,226 shares of the company's stock worth $597,395,000 after buying an additional 2,597,920 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in Kenvue by 15.7% in the 1st quarter. American Century Companies Inc. now owns 21,828,854 shares of the company's stock worth $523,456,000 after buying an additional 2,961,716 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Down 2.7%

KVUE opened at $16.21 on Tuesday. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 52 week low of $15.47 and a 52 week high of $25.17. The firm has a 50-day simple moving average of $19.03 and a two-hundred day simple moving average of $21.25. The company has a market capitalization of $31.10 billion, a PE ratio of 21.90, a price-to-earnings-growth ratio of 2.39 and a beta of 0.72.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The firm had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. During the same quarter last year, the firm earned $0.32 EPS. The firm's revenue for the quarter was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were issued a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.1%. The ex-dividend date of this dividend was Wednesday, August 13th. This is a positive change from Kenvue's previous quarterly dividend of $0.21. Kenvue's payout ratio is 112.16%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on KVUE shares. Redburn Partners set a $22.00 price target on Kenvue in a research note on Friday, September 26th. JPMorgan Chase & Co. cut their price target on Kenvue from $24.00 to $21.00 and set an "overweight" rating for the company in a research note on Friday. Barclays cut their price target on Kenvue from $20.00 to $17.00 and set an "equal weight" rating for the company in a research note on Wednesday, October 1st. Evercore ISI dropped their price objective on shares of Kenvue from $23.00 to $18.00 and set an "in-line" rating for the company in a report on Tuesday, September 23rd. Finally, Citigroup dropped their price objective on shares of Kenvue from $20.00 to $17.00 and set a "neutral" rating for the company in a report on Thursday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Kenvue presently has an average rating of "Hold" and a consensus price target of $21.18.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.